Event snippet :
top of page

Aalto inside...


Aalto Bio Reagents

  • ​​Founded in 1978

  • Market leader in the development of proteins and antibodies for new and emerging diseases eg. Chikungunya , Dengue , Zika , Sars , COVID-19 and VEEV virus

  • Custom manufacture of new recombinant antigens

  • Routine manufacture of bulk antigens and antibodies

  • Full raw material menu for chemiluminescence platforms

  • Europes largest provider of bulk disease state plasma for controls

  • Joined the Biosynth Group to form the biologics division in May 2022

  • Rebranded to Biosynth Ltd. on 1st August 2023.

bottom of page